Disease-Modifying Effects of M1 Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model

Alzheimer's disease (AD) is the leading cause of dementia worldwide, and currently no disease-modifying therapy is available to slow or prevent AD, underscoring the urgent need for neuroprotective therapies. Selective M-1, muscarinic acetylcholine receptor (mAChR) activation is an attractive mechanism for AD therapy since M-1, mediates key effects on memory, cognition, and behavior and has potential for disease-modifying effects on A beta formation and tau phosphorylation. To validate M1 as a neuroprotective treatment target for AD, the M-1-selective agonist, VU0364572, was chronically dosed to 5XFAD mice from a young age preceding A beta pathology (2 months) to an age where these mice are known to display memory impairments (6 months). Chronic M-1, activation prevented mice from becoming memory-impaired, as measured by Morris water maze (MWM) testing at 6 months of age. Additionally, M-1, activation significantly reduced levels of soluble and insoluble A beta(40,42) in the cortex and hippocampus of these animals, as measured by ELISA and immunohistochemistry. Moreover, soluble hippocampal A beta(42) levels were strongly correlated with MWM memory impairments and M-1, activation with VU0364572 abolished this correlation. Finally, VU0364572 significantly decreased oligomeric (oA beta) levels in the cortex, suggesting one mechanism whereby VU0364572 may be exerting its neuroprotective effects is by reducing the available oA beta pool in the brain. These findings suggest that chronic M-1 activation has neuroprotective potential for preventing memory impairments and reducing neuropathology in AD. M-1 activation therefore represents a promising avenue for preventative treatment, as well as a promising opportunity to combine symptomatic and diseas e-modifying effects for early AD treatment.